A feasibility, randomised controlled trial of a complex breathlessness intervention in idiopathic pulmonary fibrosis (BREEZE-IPF): study protocol
Wright, Caroline; Hart, Simon P.; Allgar, Victoria; English, Anne; Swan, Flavia; Dyson, Judith; Richardson, Gerry; Twiddy, Maureen; Cohen, Judith; Hussain, Jamilla; Johnson, Miriam; Hargreaves, Ian; Crooks, Michael G
Simon P. Hart
Dr Flavia Swan F.Swan@hull.ac.uk
Research fellow in cancer rehabilitation
Dr Maureen Twiddy M.Twiddy@hull.ac.uk
Senior Lecturer in Mixed Methods Research
Professor Miriam Johnson Miriam.Johnson@hull.ac.uk
Michael G Crooks
Introduction: Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive lung disease that causes breathlessness and cough that worsen over time, limiting daily activities and negatively impacting quality of life. Although treatments are now available that slow the rate of lung function decline, trials of these treatments have failed to show improvement in symptoms or quality of life. There is an immediate unmet need for evidenced-based interventions that improve patients' symptom burden and make a difference to everyday living. This study aims to assess the feasibility of conducting a definitive randomised controlled trial of a holistic, complex breathlessness intervention in people with IPF. Methods and analysis: The trial is a two-centre, randomised controlled feasibility trial of a complex breathlessness intervention compared with usual care in patients with IPF. 50 participants will be recruited from secondary care IPF clinics and randomised 1:1 to either start the intervention within 1 week of randomisation (fast-track group) or to receive usual care for 8 weeks before receiving the intervention (wait-list group). Participants will remain in the study for a total of 16 weeks. Outcome measures will be feasibility outcomes, including recruitment, retention, acceptability and fidelity of the intervention. Clinical outcomes will be measured to inform outcome selection and sample size calculation for a definitive trial. Ethics and dissemination: Yorkshire and The Humber-Bradford Leeds Research Ethics Committee approved the study protocol (REC 18/YH/0147). Results of the main trial and all secondary end-points will be submitted for publication in a peer-reviewed journal. @ERSpublications Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive lung disease. This study protocol describes the BREEZE-IPF study: a feasibility, randomised controlled trial of a holistic, complex breathlessness intervention in IPF. http://bit.ly/33eF9im Cite this article as: Wright C, Hart SP, Allgar V, et al. A feasibility, randomised controlled trial of a complex breathlessness intervention in idiopathic pulmonary fibrosis (BREEZE-IPF): study protocol.
|Journal Article Type||Article|
|Publication Date||Oct 22, 2019|
|Journal||ERJ Open Research|
|Publisher||European Respiratory Society|
|Peer Reviewed||Peer Reviewed|
|APA6 Citation||Crooks, M. G., Wright, C., Hart, S. P., Allgar, V., English, A., Swan, F., …Crooks, M. G. (2019). A feasibility, randomised controlled trial of a complex breathlessness intervention in idiopathic pulmonary fibrosis (BREEZE-IPF): study protocol. ERJ Open Research, 5(4), https://doi.org/10.1183/23120541.00186-2019|
Copyright ©ERS 2019
This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.
You might also like
Battery-operated fan and chronic breathlessness: does it help?